Trikafta's hidden effects: new study probes metabolism and microbiome in CF patients
NCT ID NCT07363304
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 150 cystic fibrosis patients starting the drug combination Trikafta (ETI) to see how it affects their metabolism, DNA methylation, and gut bacteria. Researchers will measure blood fats, sugars, and immune markers, and link them to drug levels. The goal is to understand why some patients develop side effects like high cholesterol or liver problems, and to find ways to personalize dosing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Elexacaftor-Tezacaftor-Ivacaftor (Trikafta/Kaftrio)
What this could lead to
If successful, this could help doctors personalize ETI dosing to reduce side effects like high cholesterol or liver issues, improving long-term care for cystic fibrosis patients.
What could go wrong
This is an observational study, not a treatment trial. It won't prove if ETI works or is safe, only track changes in the body. Results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Azienda Ospedaliera Universitaria Meyer Istituto di Ricovero e Cura a Carattere Scientifico
RECRUITINGFlorence, 5016, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro per la Fibrosi Cistica, Azienda Universitaria Ospedaliera Consorziale Policlinico
NOT_YET_RECRUITINGBari, Bari, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Centro per la Fibrosi Cistica, Ospedale Infantile Regina Margherita
NOT_YET_RECRUITINGTorino, Torino, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Dipartimento di Pediatria, Centro Fibrosi Cistica, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
NOT_YET_RECRUITINGMilan, Milano, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Ospedale pediatrico Bambino Gesù, IRCCS, Dipartimento Pediatrico Universitario Ospedaliero, UOC Pneumologia e Fibrosi Cistica
NOT_YET_RECRUITINGRoma, Roma, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Unità Pediatrica, Dipartimento di Scienze Mediche Traslazionali, Centro di Riferimento Regionale per la Fibrosi Cistica, Università degli Studi di Napoli Federico II
NOT_YET_RECRUITINGNaples, Napoli, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••